Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

448 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers.
Stjepanovic N, Lubinski J, Moller P, Randall Armel S, Foulkes WD, Tung N, Neuhausen SL, Kotsopoulos J, Sun P, Sun S, Eisen A, Narod SA; Hereditary Breast Cancer Clinical Study Group. Stjepanovic N, et al. Among authors: neuhausen sl. Breast Cancer Res Treat. 2021 Jun;187(2):515-523. doi: 10.1007/s10549-020-06072-9. Epub 2021 Jan 10. Breast Cancer Res Treat. 2021. PMID: 33423179
Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families.
Tonin P, Weber B, Offit K, Couch F, Rebbeck TR, Neuhausen S, Godwin AK, Daly M, Wagner-Costalos J, Berman D, Grana G, Fox E, Kane MF, Kolodner RD, Krainer M, Haber DA, Struewing JP, Warner E, Rosen B, Lerman C, Peshkin B, Norton L, Serova O, Foulkes WD, Garber JE, et al. Tonin P, et al. Nat Med. 1996 Nov;2(11):1179-83. doi: 10.1038/nm1196-1179. Nat Med. 1996. PMID: 8898735 Review. No abstract available.
Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers.
Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, Isaacs C, Olopade O, Garber JE, Godwin AK, Daly MB, Narod SA, Neuhausen SL, Lynch HT, Weber BL. Rebbeck TR, et al. Among authors: neuhausen sl. J Natl Cancer Inst. 1999 Sep 1;91(17):1475-9. doi: 10.1093/jnci/91.17.1475. J Natl Cancer Inst. 1999. PMID: 10469748
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.
Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, Stoppa-Lyonnet D, Lerman C, Pasini B, de los Rios P, Weber B, Lynch H; Hereditary Breast Cancer Clinical Study Group. Narod SA, et al. Among authors: neuhausen sl. Lancet. 2000 Dec 2;356(9245):1876-81. doi: 10.1016/s0140-6736(00)03258-x. Lancet. 2000. PMID: 11130383
448 results